Aurinia Pharmaceuticals(US:AUPH)2026-02-26 14:32Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [4] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [4] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024 [4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [5] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [6] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [6] - Cash flows from operating activities for Q4 2025 were $45.7 million, up 52% from $30.1 million in Q4 2024 [5] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [7] Market Data and Key Metrics Changes - The company expects net product sales of $305 million to $315 million for 2026, representing a 12%-16% increase compared to 2025 [3][8] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [7][8] Company Strategy and Development Direction - The company is focused on the commercial growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The company acknowledged the competitive landscape with the introduction of Gazyva but noted no immediate impact on LUPKYNIS sales [35] - Management emphasized the importance of awareness and aggressive treatment in growing the market for lupus nephritis [36] Other Important Information - The company terminated the phase III VOCAL study due to recruitment challenges and plans to negotiate with the FDA regarding pediatric commitments [16][17] - Management highlighted the potential for combining B-cell and T-cell therapies in treating lupus nephritis, indicating ongoing research in this area [46][47] Q&A Session Summary Question: Guidance for 2026 seems conservative; what are the underlying assumptions? - Management explained that the guidance is based on historical growth patterns and current market conditions, with no extraordinary trends observed in early 2026 [12][15] Question: Clarification on the termination of the VOCAL study and FDA's stance? - Management clarified that the study was terminated due to recruitment difficulties and that they plan to discuss pediatric commitments with the FDA [16][17] Question: Update on aritinercept development and study design? - Management confirmed that a clinical study for aritinercept has been initiated, with more details expected in Q2 2026 [20][22] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no immediate impact on LUPKYNIS sales and that the guidance incorporates various factors, including competition [35][36] Question: Are doctors combining B-cell and T-cell therapies? - Management indicated that there is potential for combining therapies and that they are exploring this in ongoing research [46][47]